National Institutes of Health Stroke Scale

Imperative Care Announces FDA Clearance of Zoom 88 Support, Designed to Bring the Benefits of Intracranial Access to More Stroke Patients

Retrieved on: 
Tuesday, July 25, 2023
Health, FDA, Medical Devices, Hospitals, Health Technology, General Health, Biotechnology, Stroke, Food and Drug Administration, Neuroradiology, LDP, Imperative, GM, Patient, Physician, NIHSS, TICI, Femoral artery, Erlanger Health System, National Institutes of Health Stroke Scale, Zoom, Support, Food, Pharmaceutical industry

Imperative Care has pioneered the use of large-bore .088” intracranial access paired with angled-tip aspiration catheters to enable better and faster reperfusion for stroke procedures.1,2 Zoom 88 Support expands the company’s .088” intracranial access portfolio – the only access portfolio on the market to enable large-bore intracranial access.

Key Points: 
  • Imperative Care has pioneered the use of large-bore .088” intracranial access paired with angled-tip aspiration catheters to enable better and faster reperfusion for stroke procedures.1,2 Zoom 88 Support expands the company’s .088” intracranial access portfolio – the only access portfolio on the market to enable large-bore intracranial access.
  • The portfolio also includes the existing Zoom 88 LDP and the Zoom RDL Access Platform.
  • Zoom 88 Support provides the same benefits of intracranial access found with Zoom 88 LDP, with the ability to treat more proximal or tandem occlusions,” said Ariel Sutton, GM of Imperative Care’s Stroke business.
  • “With products like Zoom 88 Support, Imperative Care continues to respond to the needs of patients with much-needed solutions to help streamline stroke procedures and treat patients quickly and effectively.”

Brain Awareness Week 2023: Get Ahead of Stroke® Campaign Releases New EMS Resources

Retrieved on: 
Monday, March 13, 2023
Policy, Emergency medical services, Thrombectomy, National Institutes of Health Stroke Scale, Brain, Surgeon, Ambient occlusion, MS, Foundation (nonprofit), MEND, Organization, Icahn School of Medicine at Mount Sinai, Disability, VAN, ELVO, Triage, Brain Awareness Week, Neuroradiology, Patient, Death, Multimedia, Google Play, RACE, App Store (iOS/iPadOS), New Zealand Open Source Society, Mount Sinai, Kalmon Dolgin, LAMS, EMS, Life, Dana Foundation, Get Ahead, Society, Neurosurgery, Pharmaceutical industry, Nursing, Video game, Medicine, Stroke

FAIRFAX, Va., March 13, 2023 /PRNewswire/ -- On this first day of Brain Awareness Week (March 13 – 19), the Get Ahead of Stroke® campaign is debuting new online resources for Emergency Medical Service (EMS) providers to assist stroke patients with greater efficiency and ease.

Key Points: 
  • EMS is critical to providing stroke patients their best chance to survive and thrive after stroke.
  • "During this Brain Awareness Week, we want to shine a spotlight on the lifesaving work that EMS does every day of the year, every hour of the day.
  • Get Ahead of Stroke created the Stroke Scales for EMS mobile app to help EMS identify stroke severity and ELVO in emergency situations.
  • Brain Awareness Week is a global campaign coordinated by the Dana Foundation to foster public enthusiasm and support for brain science.

Health at Scale and ATRIO Health Plans Partner on Smart AI-Powered Payment Integrity

Retrieved on: 
Monday, February 27, 2023
Safety, Intelligence, Partnership, Scale, Health, AI, Medicare, SAN, National Institutes of Health Stroke Scale, Machine learning, TPA, Prevalence, Fraud, Pharmaceutical industry

SAN JOSE, Calif., Feb. 27, 2023 /PRNewswire/ -- Health at Scale, a leading provider of machine intelligence for value-based care delivery and management, today announced a partnership with ATRIO Health Plans, Inc., a top provider of Medicare Advantage plans serving approximately 30,000 members in Oregon and Nevada. The partnership will leverage Health at Scale's state-of-the-art AI and machine learning technologies to prevent low-value care corresponding to fraud, waste, abuse and errors in real-time; and drive greater quality, safety and affordability for plan members in support of ATRIO Health Plan's mission of delivering high quality health insurance at a reasonable price for Medicare Advantage beneficiaries.

Key Points: 
  • "We are excited to partner with ATRIO Health Plans around our industry-leading capabilities to reduce fraud, waste, abuse and errors," said Zeeshan Syed, CEO of Health at Scale.
  • "Our technology has been able to meaningfully reduce low-value care for health plans – something that has been a hard problem to solve for decades and continues to drive up costs.
  • We look forward to working with ATRIO Health Plans to bring this innovative capability to their Medicare Advantage plans and to support their mission of providing high-quality, cost-effective healthcare to their members."
  • "After completing substantial due diligence of the market landscape, we have found that the tools and technology that Health at Scale offers health plans is best-in-class based on what we have seen, and look forward to working with Health at Scale across our entire book of business," said Jennifer Callahan, Chief Operating Officer of ATRIO Health Plans.

Health at Scale Awarded Patent for Breakthrough AI Technology for Smart Hyper-Personalized Provider Navigation

Retrieved on: 
Wednesday, February 8, 2023
Patent, Health, Scale, Patient, Computer science, University, National Institutes of Health Stroke Scale, Associate, Stanford University School of Medicine, SAN, Machine learning, Clinical associates, Pharmaceutical industry, Nursing

SAN JOSE, Calif., Feb. 8, 2023 /PRNewswire/ -- Health at Scale, the market leader in smart AI-powered technologies to optimize care management, announced today that it has been awarded a patent by the U.S. Patent and Trademark Office for its breakthrough advances in personalized patient-provider matching using machine learning.

Key Points: 
  • Health at Scale's patented technology transforms provider search by empowering patients to find optimal primary and specialist care provider matches specific to their unique individualized health conditions and needs.
  • This patent advances Health at Scale's mission to re-invent care delivery as a precise and personalized process that is deeply aware of each patient's unique health characteristics and circumstances at all times.
  • By rethinking the patient-provider matching process, Health at Scale drives improved outcomes, costs, satisfaction, quality and equity, while reducing unnecessary waste and cost in the system.
  • "Putting each patient's needs at the center of care management is a core element of our work at Health at Scale.

Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke

Retrieved on: 
Thursday, January 19, 2023
Health, Stem Cells, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, IND, National Institutes of Health Stroke Scale, Gene expression, MMSE, UCI, University, Mercy Gilbert Medical Center, SAFETY, AND, NIHSS, B cell, Depression, Cell proliferation, Rankine scale, Atlantic Film Festival, Rehabilitation, FDA, University of California, Horizon Fuel Cell Technologies, Patient, UCSD, Stroke, Clinical trial, Stem cell, GDS, Pharmaceutical industry, Safety

Stemedica plans to initiate a Phase IIb/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of a single intravenous injection of allogeneic mesenchymal stem cells to subjects with ischemic stroke.

Key Points: 
  • Stemedica plans to initiate a Phase IIb/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of a single intravenous injection of allogeneic mesenchymal stem cells to subjects with ischemic stroke.
  • Stemedica successfully completed a Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke in patients with chronic ischemic stroke and demonstrated an excellent safety profile of itMSCs.
  • We hope to bring this medication to patients with this debilitating condition,” said Dr. Lev Verkh, Chief Regulatory and Clinical Development Officer.
  • “Unlike other stroke trials using stem cells, this is the first clinical trial of its kind, evaluating Stemedica’s itMSCs.

Health at Scale Named to the 2022 CB Insights Digital Health 150 List

Retrieved on: 
Wednesday, December 7, 2022
CB Insights, Digital technology, R, University, AR, MIT, Fraud, Economist Intelligence Unit, Learning, National Institutes of Health Stroke Scale, Patient, Stanford University, Scale, Digital, Harvard University, Intelligence, SVP, Multimedia, Digital health, Health, SAN, Machine learning, Health literacy, Retail, Medicine, Mosaic

SAN JOSE, Calif., Dec. 7, 2022 /PRNewswire/ -- CB Insights today named Health at Scale to its fourth annual "Digital Health 150" list, showcasing the 150 most promising private digital health companies of 2022.

Key Points: 
  • SAN JOSE, Calif., Dec. 7, 2022 /PRNewswire/ -- CB Insights today named Health at Scale to its fourth annual "Digital Health 150" list, showcasing the 150 most promising private digital health companies of 2022.
  • Health at Scale is the market leader in smart hyper-personalized digital health technologies to optimize value-based care.
  • "We are honored to be included in this year's CB Insights Digital Health 150 list alongside some of the most impressive and creative companies solving the biggest challenges in healthcare," said Zeeshan Syed, Health at Scale co-founder and CEO.
  • The 2022 Digital Health 150 list recognizes Health at Scale from a pool of over 13,000 private companies.

Assured Benefits Administrators Launches AI-Powered Smart Health Plan Administration Using Health at Scale's Precision Intelligence

Retrieved on: 
Monday, December 5, 2022
Intelligence, University, MIT, Fraud, Learning, Partnership, National Institutes of Health Stroke Scale, Patient, Stanford University, Scale, Harvard University, ABA, Health, Health equity, Multimedia, SAN, Machine learning, Health literacy, Medicine, Medical device, Health insurance

SAN JOSE, Calif., Dec. 5, 2022 /PRNewswire/ -- Health at Scale, the market leader in machine intelligence for value-based care delivery, today announced a partnership with Assured Benefits Administrators (ABA), a leading national third party administrator providing flexible and fully integrated healthcare administration and management solutions to employers across the United States, to bring AI-powered smart health plan administration capabilities to ABA members.

Key Points: 
  • "We strongly believe that sustainable healthcare costs can only result from smarter health plan administration that understands each patient's unique needs and circumstances in the moment.
  • ABA's track record of administering innovative self-funded health plans makes them the perfect partner for us."
  • Assured Benefits Administrators, is a full service third party administrator providing flexible and fully integrated healthcare administration and management solutions to employers across the United States.
  • Since 1985, ABA has been offering innovative, cost-efficient health benefits to self-funded plan sponsors that are a strategic asset and not just an added cost.

Health at Scale Welcomes Dr. Andrew Lo to Advisory Board

Retrieved on: 
Tuesday, September 27, 2022
People, Computer science, Health policy, Empathy, Market share, Time, Machine learning, National Institutes of Health Stroke Scale, World, TIME, University of Michigan, MIT, Principal, Senior, MIT Sloan School of Management, Public policy, Perelman School of Medicine at the University of Pennsylvania, Economics, Medicare Payment Advisory Commission, Learning, Partnership, Harvard University, Patient, Book, Intelligence, MIT Laboratory for Information and Decision Systems, Health, Scale, Technology, CEO, CSAIL, Stanford University, MIT Computer Science and Artificial Intelligence Laboratory, Abuse, Fraud, Financial engineering, Harvard Medical School, White House, SAN, Multimedia, University, View, Artificial Intelligence Laboratory, Medical device, Medicine

SAN JOSE, Calif., Sept. 27, 2022 /PRNewswire/ -- Health at Scale today announced the addition of Dr. Andrew W. Lo to its external advisory board.

Key Points: 
  • SAN JOSE, Calif., Sept. 27, 2022 /PRNewswire/ -- Health at Scale today announced the addition of Dr. Andrew W. Lo to its external advisory board.
  • Lo serves as the Director of the MIT Laboratory for Financial Engineering and a Principal Investigator of MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL).
  • "Health at Scale is changing the way we think about healthcare management.
  • Lo co-founded QLS Advisors LLC , a life sciences technology and investment advisory company dedicated to fostering biomedical innovation.

GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)

Retrieved on: 
Monday, September 19, 2022
II, NIHSS, Safety, Human, COVID-19, Cell biology, National Institutes of Health Stroke Scale, National, Ophthalmology, Administration, Stroke, NMDA, IND, Efficacy, MRI, Psychology, Patient, BI, IDMC, CEO, III, Odds ratio, TPA, MRS, SONIC, Neuroprotection, Connective tissue disease, MFDS, Toxicity, Pharmacology, NR2B, Thrombectomy, Reperfusion, Research, Cerebral infarction, GLOBE, Mortality, GNTP, GNT, Rankine scale, Antioxidant, Brain, Pharmaceutical industry, Vaccine, Food, Neurology

Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies.

Key Points: 
  • Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies.
  • In the prior phase II trial in China (ENIS, 237 patients), administration of nelonemdaz reduced disability primarily in moderate to severe ischemic stroke patients treated with a thrombolytic drug.
  • The ENIS-3 trial was then designed to examine the efficacy and safety of nelonemdaz in 946 patients with moderate to severe acute ischemic stroke treated with tPA within 8 hours of stroke onset.
  • In China, a phase II study of nelonemdaz (ENIS trial) has been completed in acute ischemic stroke patients receiving a thrombolytic drug within 8 hours of stroke onset (n=237).

Imperative Care Announces Positive New Data Underscoring the Safety and Efficacy of the Zoom Stroke Solution to Treat Distal Occlusions in Ischemic Stroke Patients

Retrieved on: 
Wednesday, August 24, 2022
General Health, Neurology, Medical Devices, Other Health, Health, COO, Moyamoya disease, Technology, National Institute, Safety, Zoom, MCA, Brain, Intracranial hemorrhage, Solution, National Institutes of Health Stroke Scale, Contraindication, Physician, STAR, IQR, Veni, vidi, vici, Intervention, Annual general meeting, AJNR, Middle cerebral artery, Stroke, Reperfusion, World government, Risk, Patient, Anatomical terms of location, Medical device, Dentistry, Pharmaceutical industry, SWIFT

today announced that new data evaluating the utility of the Zoom Stroke Solution were presented at the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) 2022 Annual Meeting in Kyoto.

Key Points: 
  • today announced that new data evaluating the utility of the Zoom Stroke Solution were presented at the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) 2022 Annual Meeting in Kyoto.
  • The Zoom Stroke Solution is the complete stroke system from access through reperfusion for fast and effective clot removal for patients with acute ischemic stroke.
  • The system includes the Zoom 88 Large Distal Platform for neurovascular access, four vessel-matched Zoom Aspiration Catheters, the Zoom Pump, the Zoom POD and other accessories.
  • Imperative Care and Truvic are based in Campbell, Calif. https://imperativecare.com
    + Dr. Torok is a paid consultant for Imperative Care.